These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 35316579)

  • 1. Effect of Colonic Absorption on the Pharmacokinetic Properties of Delayed-Release and Extended-Release Methylphenidate: In Vivo, In Vitro, and Modeling Evaluations.
    Incledon B; Incledon C; Gomeni R; Uchida CL; Morris A; Perry K; Kapuscinski J
    Clin Pharmacol Drug Dev; 2022 Aug; 11(8):966-975. PubMed ID: 35316579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate: Evaluation of Dose Proportionality, Food Effect, Multiple-Dose Modeling, and Comparative Bioavailability with Immediate-Release Methylphenidate in Healthy Adults.
    Liu T; Gobburu JVS; Po MD; McLean A; DeSousa NJ; Sallee FR; Incledon B
    J Child Adolesc Psychopharmacol; 2019 Apr; 29(3):181-191. PubMed ID: 30810347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-Dose Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate Formulation, in Healthy Adults and in Adolescents and Children with Attention-Deficit/Hyperactivity Disorder.
    Childress A; Mehrotra S; Gobburu J; McLean A; DeSousa NJ; Incledon B
    J Child Adolesc Psychopharmacol; 2018 Feb; 28(1):10-18. PubMed ID: 29039979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).
    Swanson JM; Wigal SB; Wigal T; Sonuga-Barke E; Greenhill LL; Biederman J; Kollins S; Nguyen AS; DeCory HH; Hirshe Dirksen SJ; Hatch SJ;
    Pediatrics; 2004 Mar; 113(3 Pt 1):e206-16. PubMed ID: 14993578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Post Hoc Comparison of Prior ADHD Medication Dose and Optimized Delayed-release and Extended-release Methylphenidate Dose in a Pivotal Phase III Trial.
    Childress AC; Uchida CL; Po MD; DeSousa NJ; Incledon B
    Clin Ther; 2020 Dec; 42(12):2332-2340. PubMed ID: 33168234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Model-Based Approach for Establishing the Predicted Clinical Response of a Delayed-Release and Extended-Release Methylphenidate for the Treatment of Attention-Deficit/Hyperactivity Disorder.
    Gomeni R; Komolova M; Incledon B; Faraone SV
    J Clin Psychopharmacol; 2020; 40(4):350-358. PubMed ID: 32590405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder.
    Pliszka SR; Wilens TE; Bostrom S; Arnold VK; Marraffino A; Cutler AJ; López FA; DeSousa NJ; Sallee FR; Incledon B; Newcorn JH
    J Child Adolesc Psychopharmacol; 2017 Aug; 27(6):474-482. PubMed ID: 29172680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Comparison of the Pharmacokinetics of Methylphenidate Extended-Release Orally Disintegrating Tablets With a Reference Extended-Release Formulation of Methylphenidate in Healthy Adults.
    Childress A; Stark JG; McMahen R; Engelking D; Sikes C
    Clin Pharmacol Drug Dev; 2018 Feb; 7(2):151-159. PubMed ID: 28544581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
    Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M
    Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults.
    Markowitz JS; Straughn AB; Patrick KS; DeVane CL; Pestreich L; Lee J; Wang Y; Muniz R
    Clin Pharmacokinet; 2003; 42(4):393-401. PubMed ID: 12648029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Randomized, Double-Blind, Placebo-Controlled Study of HLD200, a Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder: An Evaluation of Safety and Efficacy Throughout the Day and Across Settings.
    Childress AC; Cutler AJ; Marraffino A; McDonnell MA; Turnbow JM; Brams M; DeSousa NJ; Incledon B; Sallee FR; Wigal SB
    J Child Adolesc Psychopharmacol; 2020 Feb; 30(1):2-14. PubMed ID: 31464511
    [No Abstract]   [Full Text] [Related]  

  • 12. Single-dose pharmacokinetics of methylphenidate extended-release multiple layer beads administered as intact capsule or sprinkles versus methylphenidate immediate-release tablets (Ritalin(®)) in healthy adult volunteers.
    Adjei A; Teuscher NS; Kupper RJ; Chang WW; Greenhill L; Newcorn JH; Connor DF; Wigal S
    J Child Adolesc Psychopharmacol; 2014 Dec; 24(10):570-8. PubMed ID: 25514542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in the in vitro and in vivo pharmacokinetic profiles of once-daily modified-release methylphenidate formulations in Canada: examination of current bioequivalence criteria.
    Shram MJ; Quinn AM; Chen N; Faulknor J; Luong D; Sellers EM; Endrenyi L
    Clin Ther; 2012 May; 34(5):1170-81. PubMed ID: 22512898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Single-Dose, Single-Period Pharmacokinetic Assessment of an Extended-Release Orally Disintegrating Tablet of Methylphenidate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
    Childress A; Newcorn J; Stark JG; McMahen R; Tengler M; Sikes C
    J Child Adolesc Psychopharmacol; 2016 Aug; 26(6):505-12. PubMed ID: 27228207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of modified-release methylphenidate in the treatment of attention-deficit/hyperactivity disorder.
    Childress A; Belchenko D; Lempa B
    Expert Rev Neurother; 2017 Feb; 17(2):113-121. PubMed ID: 27936986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-dose Pharmacokinetic Properties and Relative Bioavailability of a Novel Methylphenidate Extended-release Chewable Tablet Compared With Immediate-release Methylphenidate Chewable Tablet.
    Abbas R; Palumbo D; Walters F; Belden H; Berry SA
    Clin Ther; 2016 May; 38(5):1151-7. PubMed ID: 27021606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Similar bioavailability of dexmethylphenidate extended (bimodal) release, dexmethyl-phenidate immediate release and racemic methylphenidate extended (bimodal) release formulations in man.
    Tuerck D; Wang Y; Maboudian M; Wang Y; Sedek G; Pommier F; Appel-Dingemanse S
    Int J Clin Pharmacol Ther; 2007 Dec; 45(12):662-8. PubMed ID: 18184535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The single-dose pharmacokinetics of NWP06, a novel extended-release methylphenidate oral suspension.
    Childress AC; Berry SA
    Postgrad Med; 2010 Sep; 122(5):35-41. PubMed ID: 20861586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Model-Based Approach for Optimizing Study Design and Clinical Drug Performances of Extended-Release Formulations of Methylphenidate for the Treatment of ADHD.
    Gomeni R; Bressolle-Gomeni F; Spencer TJ; Faraone SV; Fang L; Babiskin A
    Clin Pharmacol Ther; 2017 Dec; 102(6):951-960. PubMed ID: 28369788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population Pharmacokinetic-Pharmacodynamic Modeling of a Novel Methylphenidate Extended-Release Orally Disintegrating Tablet in Pediatric Patients With Attention-Deficit/Hyperactivity Disorder.
    Teuscher NS; Sikes CR; McMahen R; Engelking D
    J Clin Psychopharmacol; 2018 Oct; 38(5):467-474. PubMed ID: 30119076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.